Cisplatin News and Research

RSS

Use of DNA-damaging agents revolutionizes chemotherapy against a wide variety of cancers

A new study demonstrates the potential effectiveness of treating tumors by combining agents that damage DNA with a drug that sensitizes cancer cells to these agents.

28 Mar 2005

Researchers turn fatal brain cancer into treatable disease for children

Some children with a rare brain tumor that is considered almost universally fatal can be saved if they receive radiation therapy followed by tandem (given one after the other) cycles of high-dose chemotherapy.

3 Mar 2005

Discovery of new compound known as SP-4-84 could lead to improved chemotherapy treatments

The discovery of a new compound by Michigan State University researchers could lead to improved chemotherapy treatments for different types of cancers – potentially with fewer side effects.

20 Dec 2004

FDA approves Tarceva (erlotinib)

OSI Pharmaceuticals and Genentech have announced that the U.S. Food and Drug Administration (FDA) has approved, after priority review, Tarceva (erlotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.

20 Nov 2004

FDA fast tracks investigational anti-cancer drug, phenoxodiol

Marshall Edwards today announced that the U.S. Food and Drug Administration (FDA) has granted the investigational anti-cancer drug, phenoxodiol, Fast Track status for its intended use in patients with recurrent ovarian cancer.

4 Nov 2004

Alimta approved as first treatment for Mesothelioma, a deadly cancer caused by asbestos

Lilly UK announced today that Alimta( (pemetrexed) will be available shortly for the treatment of people diagnosed with mesothelioma, a cancer of the lining of the lungs for which there is no known cure. Pemetrexed is the first licenced treatment for malignant pleural mesothelioma, in combination with cisplatin.

1 Nov 2004

Study hints at antioxidants being able to prevent and restore hearing loss

In a preliminary study, researchers find that vitamin E may be effective in restoring sudden onset hearing loss of unknown origin (idiopathic sudden hearing loss). These findings suggest that further research may reveal the role of antioxidants in the prevention and restoration of hearing loss.

18 Sep 2004

Aggressive treatment for nasopharyngeal cancer shown to be more effective

Radiation therapy (RT) has been the most important treatment modality with curative potential in treating patients with cancer of the nasopharynx, the part of the pharynx that lies above the soft palate.

9 Aug 2004

Alimta receives positive endorsement for lung cancer approval from FDA Advisory Committee

Eli Lilly and Company have announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration positively endorsed Alimta® (pemetrexed), an antifolate, for accelerated approval in the second-line treatment of non-small cell lung cancer.

29 Jul 2004

Genetically engineering viruses to carry a suicide gene into ovarian cancer cells

Genetically engineering viruses to carry a suicide gene into ovarian cancer cells could become a potent way to tackle the disease, a leading Cancer Research UK scientist reveals at a conference in Glasgow today (Tuesday).

22 Jun 2004

Study may help oncologists tailor chemotherapy to patients based on their genetic make-up

Genetic variations in an individual’s ability to repair DNA damage may help predict survival in lung cancer patients treated with the common chemotherapy drugs cisplatin or carboplatin, a new study shows.

2 Jun 2004

Drug combo effective for advanced breast cancer

A pair of studies at UCLA's Jonsson Cancer Center that takes laboratory science to the patients' bedside found that combining the molecularly targeted therapy Herceptin with a specific chemotherapy combination resulted in significant tumor response rates and longer relapse-free periods in women with an aggressive form of advanced breast cancer.

19 May 2004

Discovery of molecular switch could lead to new treatments for lymphoma and other forms of cancer

Turning a vital component of cancer cells from bodyguard to assassin could form the basis of new cancer treatments, according to a report published this week.

4 May 2004

Myriad Genetics advances drug for chemotherapy-induced nausea

Myriad Genetics, Inc. today released new data on MPC-4505, its Neurokinin-1 (NK1) receptor antagonist, a drug candidate for chemotherapy-induced nausea and vomiting (emesis). MPC-4505 is a potent, orally bioavailable, CNS-penetrating, highly selective NK1 antagonist.

20 Apr 2004

NeoRx Corporation acquires worldwide rights to platinum-based anti-cancer agent

NeoRx Corporation today announced that it has acquired from AnorMED Inc. the worldwide exclusive rights, excluding Japan, to develop, manufacture and commercialize AMD473, a platinum-based anti-cancer agent. AMD473 has been administered to more than 500 cancer patients in phase I and phase II clinical trials, demonstrating anti-cancer activity in a wide range of tumors and a manageable safety profile. NeoRx expects to initiate clinical studies of AMD473 in one or more cancer indications in the second half of this year.

5 Apr 2004